There was fetal mistake in AZD1419 trial protocol design, that is, it assumed that a few doses AZD1419 would fix asthma patient immune system for at least 39 weeks(52-13) without any further medication. That was why I thought AZD1419/placebo were given to participants over 52 week treatment period.
Anyway, I would not say this is total failure until we see the detail data, AZD1419 could still be move from phase IIA into phase IIB trial if AZD1419 phase IIA data show effectiveness in certain period less than 39 weeks comparing to placebo. Hopefully AZD1419 phase IIA data will help to design the right phase IIB dose period